Research programme: cyclic peptide therapies - advanceCor
Latest Information Update: 10 Oct 2024
At a glance
- Originator advanceCor
- Class Cyclic peptides; Eye disorder therapies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Graves' disease
Most Recent Events
- 10 Sep 2024 Advancecor has patent protection for 'Cyclic peptides for the treatment of graves' disease' in European Union
- 10 Sep 2024 Preclinical trials in Graves' disease in Germany (Parenteral) prior to September 2024 (advanceCOR pipeline, September 2024)
- 10 Sep 2024 German Federal Institute for Drugs and Medical Devices (BfArM) and the European Medicines Agency approves clinical trial application for cyclopeptide in treatment of Grave's disease in Germany (advanceCor pipeline, September 2024)